ABSTRACT
OBJECTIVES Examine age differences in SARS-CoV-2 transmission risk from primary cases and infection risk among household contacts, and symptoms among those with SARS-CoV-2 infection.
METHODS People with SARS-CoV-2 infection in Nashville, Tennessee and central and western Wisconsin and their household contacts were followed daily for 14 days to ascertain symptoms and secondary transmission events. Households were enrolled between April 2020 and April 2021. Secondary infection risks (SIR) by age of the primary case and contacts were estimated using generalized estimating equations.
RESULTS The 226 primary cases were followed by 197 (49%) secondary SARS-CoV-2 infections among 404 household contacts. Age group-specific SIR among contacts ranged from 35% to 53%, with no differences by age. SIR was lower from primary cases aged 12-17 years than from primary cases 18-49 years (risk ratio [RR] 0.42; 95% confidence interval [CI] 0.19-0.92). SIR was 56% and 45%, respectively, among primary case-contact pairs in the same versus different age group (RR 1.54; 95% CI 1.03-2.31). SIR was highest among primary case-contacts pairs aged ≥65 years (77%) and 5-11 years (70%). Among secondary SARS-CoV-2 infections, 19% were asymptomatic; there was no difference in the frequency of asymptomatic infections by age group.
CONCLUSIONS Both children and adults can transmit and are susceptible to SARS-CoV-2 infection. SIR did not vary by age, but further research is needed to understand age-related differences in probability of transmission from primary cases by age.
Competing Interest Statement
NBH reports grants from Sanofi and Quidel. CGG reports grants from Campbell Alliance/Syneos, the National Institutes of Health, the Food and Drug Administration, the Agency for Health Care Research and Quality and Sanofi-Pasteur, and consultation fees from Pfizer, Merck, and Sanofi-Pasteur. Other authors have no conflicts of interest relevant to this article to disclose.
Funding Statement
Funding/Support: This study was supported by the Centers for Disease Control and Prevention, (cooperative agreements IP001078 and IP001083). Dr. Grijalva was supported in part by the National Institute for Allergy and Infectious Diseases (K24 AI148459). The work used REDCap, which is supported by CTSA award No. UL1 TR002243 from the National Center for Advancing Translational Sciences. Role of Funder/Sponsor: Investigators at the Centers for Disease Control and Prevention contributed to the design and conduct of the study. Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by Institutional Review Boards at Vanderbilt University Medical Center and Marshfield Clinic Health System. The Centers for Disease Control and Prevention (CDC) determined this activity was conducted consistent with applicable federal law and CDC policy (see 45 C.F.R. part 46; 21 C.F.R. part 56).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures: NBH reports grants from Sanofi and Quidel. CGG reports grants from Campbell Alliance/Syneos, the National Institutes of Health, the Food and Drug Administration, the Agency for Health Care Research and Quality and Sanofi-Pasteur, and consultation fees from Pfizer, Merck, and Sanofi-Pasteur. Other authors have no conflicts of interest relevant to this article to disclose.
Funding/Support: This study was supported by the Centers for Disease Control and Prevention, (cooperative agreements IP001078 and IP001083). Dr. Grijalva was supported in part by the National Institute for Allergy and Infectious Diseases (K24 AI148459). The work used REDCap, which is supported by CTSA award No. UL1 TR002243 from the National Center for Advancing Translational Sciences.
Role of Funder/Sponsor: Investigators at the Centers for Disease Control and Prevention contributed to the design and conduct of the study.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.
Data Availability
De-identified dataset can be made available upon request
Abbreviations
- CDC
- Centers for Disease Control and Prevention
- CI
- Confidence interval
- GEE
- General estimating equations
- IQR
- Interquartile range
- MCHS
- Marshfield Clinic Health System
- OR
- Odds ratio
- RR
- Risk ratio
- rRT-PCR
- Real-time reverse transcription polymerase chain reaction
- SD
- Standard deviation
- SIR
- Secondary infection risk
- US
- United States
- VUMC
- Vanderbilt University Medical Center
